BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL;  HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493-502. [PMID: 19852963 DOI: 10.1053/j.gastro.2009.10.031] [Cited by in Crossref: 338] [Cited by in F6Publishing: 303] [Article Influence: 26.0] [Reference Citation Analysis]
Number Citing Articles
1 Wong GLH. Optimal surveillance program for hepatocellular carcinoma - getting ready, but not yet. World J Hepatol 2015; 7(18): 2133-2135 [PMID: 26328024 DOI: 10.4254/wjh.v7.i18.2133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
2 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 771] [Article Influence: 130.2] [Reference Citation Analysis]
3 Ding Y, Sun Z, Zhang S, Li Y, Han X, Xu Q, Zhou L, Xu H, Bai Y, Xu C, Ding H, Ge Y, Wang W. Downregulation of snoRNA SNORA52 and Its Clinical Significance in Hepatocellular Carcinoma. Biomed Res Int 2021;2021:7020637. [PMID: 34195281 DOI: 10.1155/2021/7020637] [Reference Citation Analysis]
4 Xia H, Huang Z, Liu S, Zhao X, He R, Wang Z, Shi W, Chen W, Li Z, Yu L, Huang P, Kang P, Su Z, Xu Y, Yam JWP, Cui Y. Exosomal Non-Coding RNAs: Regulatory and Therapeutic Target of Hepatocellular Carcinoma. Front Oncol 2021;11:653846. [PMID: 33869059 DOI: 10.3389/fonc.2021.653846] [Reference Citation Analysis]
5 Tao LP, Fan XP, Fan YC, Zhao J, Gao S, Wang K. Combined detection of insulin-like growth factor-binding protein 7 promoter methylation improves the diagnostic efficacy of AFP in hepatitis B virus-associated hepatocellular carcinoma. Pathol Res Pract 2018;214:144-50. [PMID: 29108923 DOI: 10.1016/j.prp.2017.10.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Holah NS, El-Azab DS, Aiad HAE, Sweed DMM. The Diagnostic Role of SPINK1 in Differentiating Hepatocellular Carcinoma From Nonmalignant Lesions. Appl Immunohistochem Mol Morphol 2017;25:703-11. [PMID: 27028242 DOI: 10.1097/PAI.0000000000000363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, Porter G, Kachura JR, Rasuli P, Gill S, Ghali P, Chaudhury P, Siddiqui J, Valenti D, Weiss A, Wong R. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 2011;18:228-40. [PMID: 21980250 DOI: 10.3747/co.v18i5.952] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
8 Tan H, Martin P. Care of the Liver Transplant Candidate. Clinics in Liver Disease 2011;15:779-806. [DOI: 10.1016/j.cld.2011.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Sengupta S, Parikh ND. Biomarker development for hepatocellular carcinoma early detection: Current and future perspectives. Hepat Oncol. 2017;4:111-122. [PMID: 30191058 DOI: 10.2217/hep-2017-0019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
10 Zheng SG, Xu HX, Liu LN. Management of hepatocellular carcinoma: The role of contrast-enhanced ultrasound. World J Radiol 2014; 6(1): 7-14 [PMID: 24578787 DOI: 10.4329/wjr.v6.i1.7] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
11 Gopal P, Singal AG. Reply: To PMID 24095974. Clin Gastroenterol Hepatol 2014;12:2139-40. [PMID: 25176226 DOI: 10.1016/j.cgh.2014.08.030] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Kanaan N, Raggi C, Goffin E, De Meyer M, Mourad M, Jadoul M, Beguin C, Kabamba B, Borbath I, Pirson Y. Outcome of hepatitis B and C virus-associated hepatocellular carcinoma occurring after renal transplantation. J Viral Hepat. 2017;24:430-435. [PMID: 27917563 DOI: 10.1111/jvh.12655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes 2019;3:302-10. [PMID: 31485568 DOI: 10.1016/j.mayocpiqo.2019.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
14 Wang Y, Wang M, Li H, Chen K, Zeng H, Bi X, Zhu Z, Jiao Y, Wang Y, Zhu J, Zhao H, Liu X, Dai C, Fan C, Zhao C, Guo D, Zhao H, Zhou J, Wang D, Wu Z, Zhao X, Cui W, Zhang X, Cai J, Chen W, Qu C. A male-ABCD algorithm for hepatocellular carcinoma risk prediction in HBsAg carriers. Chin J Cancer Res 2021;33:352-63. [PMID: 34321832 DOI: 10.21147/j.issn.1000-9604.2021.03.07] [Reference Citation Analysis]
15 Gonzalez SA, Keeffe EB. Diagnosis of hepatocellular carcinoma: role of tumor markers and liver biopsy. Clin Liver Dis. 2011;15:297-306, vii-vix. [PMID: 21689614 DOI: 10.1016/j.cld.2011.03.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
16 Lee IC, Huang YH, Chan CC, Huo TI, Chu CJ, Lai CR, Lee PC, Su CW, Hung HH, Wu JC, Lin HC, Lee SD. Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: a novel role of alpha-fetoprotein. Liver Int 2010;30:1161-8. [PMID: 20557454 DOI: 10.1111/j.1478-3231.2010.02301.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
17 Bird TG, Dimitropoulou P, Turner RM, Jenks SJ, Cusack P, Hey S, Blunsum A, Kelly S, Sturgeon C, Hayes PC. Alpha-Fetoprotein Detection of Hepatocellular Carcinoma Leads to a Standardized Analysis of Dynamic AFP to Improve Screening Based Detection. PLoS One. 2016;11:e0156801. [PMID: 27308823 DOI: 10.1371/journal.pone.0156801] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
18 Martini A, Gallotta A, Pontisso P, Fassina G. Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C. World J Hepatol 2015; 7(29): 2913-2919 [PMID: 26689503 DOI: 10.4254/wjh.v7.i29.2913] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
19 Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol 2016; 22(1): 232-252 [PMID: 26755873 DOI: 10.3748/wjg.v22.i1.232] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
20 Sato M, Morimoto K, Kajihara S, Tateishi R, Shiina S, Koike K, Yatomi Y. Machine-learning Approach for the Development of a Novel Predictive Model for the Diagnosis of Hepatocellular Carcinoma. Sci Rep. 2019;9:7704. [PMID: 31147560 DOI: 10.1038/s41598-019-44022-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
21 Attallah AM, El-Far M, Abdelrazek MA, Omran MM, Attallah AA, Elkhouly AA, Elkenawy HM, Farid K. Combined use of nuclear phosphoprotein c-Myc and cellular phosphoprotein p53 for hepatocellular carcinoma detection in high-risk chronic hepatitis C patients. Br J Biomed Sci 2017;74:170-5. [PMID: 28705056 DOI: 10.1080/09674845.2017.1334739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
22 Natu A, Singh A, Gupta S. Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities. World J Hepatol 2021; 13(11): 1568-1583 [PMID: 34904030 DOI: 10.4254/wjh.v13.i11.1568] [Reference Citation Analysis]
23 Berretta M, Cavaliere C, Alessandrini L, Stanzione B, Facchini G, Balestreri L, Perin T, Canzonieri V. Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget. 2017;8:14192-14220. [PMID: 28077782 DOI: 10.18632/oncotarget.13929] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 6.6] [Reference Citation Analysis]
24 Shi M, Chen MS, Sekar K, Tan CK, Ooi LL, Hui KM. A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma. Eur J Cancer. 2014;50:928-936. [PMID: 24332572 DOI: 10.1016/j.ejca.2013.11.026] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
25 Wang M, Xie F, Lin J, Zhao Y, Zhang Q, Liao Z, Wei P. Diagnostic and Prognostic Value of Circulating CircRNAs in Cancer. Front Med (Lausanne) 2021;8:649383. [PMID: 33816529 DOI: 10.3389/fmed.2021.649383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Shoreibah MG, Bloomer JR, McGuire BM, Massoud OI. Surveillance for hepatocellular carcinoma: evidence, guidelines and utilization. Am J Med Sci. 2014;347:415-419. [PMID: 24759379 DOI: 10.1097/maj.0000000000000200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
27 Kim MN, Kim BK, Kim SU, Park JY, Ahn SH, Han KH, Kim DY. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scand J Gastroenterol 2019;54:1283-90. [PMID: 31593481 DOI: 10.1080/00365521.2019.1673478] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
28 Kuo YT, Chen CY, Liu GC, Wang YM. Development of Bifunctional Gadolinium-Labeled Superparamagnetic Nanoparticles (Gd-MnMEIO) for In Vivo MR Imaging of the Liver in an Animal Model. PLoS One 2016;11:e0148695. [PMID: 26886558 DOI: 10.1371/journal.pone.0148695] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
29 McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis. 2010;14:461-476. [PMID: 20638025 DOI: 10.1016/j.cld.2010.05.009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
30 Chaminda SR, Suchintha T, Anuk NM, Supun DA, Bhagya GM, Habarakada LCA, Janaka SH. Pre-treatment alphafeto protein in hepatocellular carcinoma with non-viral aetiology - a prospective study. BMC Gastroenterol 2017;17:142. [PMID: 29207969 DOI: 10.1186/s12876-017-0710-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Hsieh SY, He JR, Yu MC, Lee WC, Chen TC, Lo SJ, Bera R, Sung CM, Chiu CT. Secreted ERBB3 isoforms are serum markers for early hepatoma in patients with chronic hepatitis and cirrhosis. J Proteome Res 2011;10:4715-24. [PMID: 21877752 DOI: 10.1021/pr200519q] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
32 Zhu R, Yang J, Xu L, Dai W, Wang F, Shen M, Zhang Y, Zhang H, Chen K, Cheng P. Diagnostic Performance of Des-γ-carboxy Prothrombin for Hepatocellular Carcinoma: A Meta-Analysis. Gastroenterol Res Pract. 2014;2014:529314. [PMID: 25165471 DOI: 10.1155/2014/529314] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
33 Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol. 2014;28:843-853. [PMID: 25260312 DOI: 10.1016/j.bpg.2014.07.018] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
34 Shen P, Si J, Li QW, Qu LL, Li LR, Yan XL, Ji GZ. Human des-γ-carboxy prothrombin: Cloning, expression and monoclonal antibody preparation. Shijie Huaren Xiaohua Zazhi 2013; 21(35): 3932-3939 [DOI: 10.11569/wcjd.v21.i35.3932] [Reference Citation Analysis]
35 Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2015; 21(37): 10573-10583 [PMID: 26457017 DOI: 10.3748/wjg.v21.i37.10573] [Cited by in CrossRef: 188] [Cited by in F6Publishing: 182] [Article Influence: 26.9] [Reference Citation Analysis]
36 Notake T, Kobayashi A, Shinkawa H, Kawahara T, Shimizu A, Yokoyama T, Hasegawa K, Kokudo N, Matsuyama Y, Makuuchi M, Miyagawa SI. Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection. Int J Clin Oncol 2017;22:715-25. [PMID: 28303401 DOI: 10.1007/s10147-017-1114-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
37 Yang M, Zhang X, Liu J. Prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: A systematic review and meta-analysis. PLoS One 2019;14:e0225170. [PMID: 31730646 DOI: 10.1371/journal.pone.0225170] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
38 James J, Liou IW. Comprehensive Care of Patients with Chronic Liver Disease. Medical Clinics of North America 2015;99:913-33. [DOI: 10.1016/j.mcna.2015.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
39 Meguro M, Mizuguchi T, Nishidate T, Okita K, Ishii M, Ota S, Ueki T, Akizuki E, Hirata K. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients. World J Gastroenterol 2015; 21(16): 4933-4945 [PMID: 25945007 DOI: 10.3748/wjg.v21.i16.4933] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
40 Kim BS. Noninvasive diagnosis of hepatocellular carcinoma. Clin Mol Hepatol 2012;18:245-7. [PMID: 22893878 DOI: 10.3350/cmh.2012.18.2.245] [Reference Citation Analysis]
41 Morimoto M, Numata K, Nozaki A, Kondo M, Moriya S, Taguri M, Morita S, Konno M, Sugo A, Miyajima E, Maeda S, Tanaka K. Novel Lens culinaris agglutinin-reactive fraction of α-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low α-fetoprotein concentrations. Int J Clin Oncol 2012;17:373-9. [PMID: 21847534 DOI: 10.1007/s10147-011-0306-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
42 Zhao Q, Liu YY, Lei X, Lei FF, Li G, Li F, Li JK, Yang J, Liu L, Tan HB. PIVKA-Ⅱ as a screening marker for hepatocellular carcinoma in patients with hepatitis B virus infection. Shijie Huaren Xiaohua Zazhi 2017; 25(9): 803-809 [DOI: 10.11569/wcjd.v25.i9.803] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
43 Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012;55:483-90. [PMID: 21953299 DOI: 10.1002/hep.24703] [Cited by in Crossref: 185] [Cited by in F6Publishing: 184] [Article Influence: 16.8] [Reference Citation Analysis]
44 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
45 Fetzer DT, Rodgers SK, Harris AC, Kono Y, Wasnik AP, Kamaya A, Sirlin C. Screening and Surveillance of Hepatocellular Carcinoma: An Introduction to Ultrasound Liver Imaging Reporting and Data System. Radiol Clin North Am 2017;55:1197-209. [PMID: 28991560 DOI: 10.1016/j.rcl.2017.06.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
46 Snow KK, Bell MC, Stoddard AM, Curto TM, Wright EC, Dienstag JL. Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials 2014;15:159. [PMID: 24886378 DOI: 10.1186/1745-6215-15-159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
47 Wong KF, Luk JM. Discovery of lamin B1 and vimentin as circulating biomarkers for early hepatocellular carcinoma. Methods Mol Biol 2012;909:295-310. [PMID: 22903723 DOI: 10.1007/978-1-61779-959-4_19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
48 Singal AG, Parikh ND, Rich NE, John BV, Pillai A. Hepatocellular Carcinoma Surveillance and Staging. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 27-51. [DOI: 10.1007/978-3-030-21540-8_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Adamopoulos PG, Tsiakanikas P, Scorilas A. Kallikrein-related peptidases and associated microRNAs as promising prognostic biomarkers in gastrointestinal malignancies. Biological Chemistry 2018;399:821-36. [DOI: 10.1515/hsz-2017-0342] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
50 Ma XL, Zhu J, Wu J, Tian L, Gao YY, Zhang CY, Zhou Y, Dai Q, Wang BL, Pan BS, Zhou J, Fan J, Yang XR, Guo W. Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma. Oncol Lett 2018;15:8396-404. [PMID: 29805574 DOI: 10.3892/ol.2018.8375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
51 Mitchell JK, McGivern DR. Mechanisms of hepatocarcinogenesis in chronic hepatitis C. Hepat Oncol 2014;1:293-307. [PMID: 30190964 DOI: 10.2217/hep.14.7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
52 Gibriel AA, Al-anany AM, Al-arab MAE, Azzazy HME. Investigating circulatory microRNA expression profiles in Egyptian patients infected with hepatitis C virus mediated hepatic disorders. Meta Gene 2020;26:100792. [DOI: 10.1016/j.mgene.2020.100792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
53 Wu M, Liu Z, Li X, Zhang A, Li N. Dynamic Changes in Serum Markers and Their Utility in the Early Diagnosis of All Stages of Hepatitis B-Associated Hepatocellular Carcinoma. Onco Targets Ther. 2020;13:827-840. [PMID: 32095079 DOI: 10.2147/ott.s229835] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
54 Colli A, Nadarević T, Miletić D, Giljaca V, Fraquelli M, Štimac D, Casazza G; Cochrane Hepato-Biliary Group. Abdominal ultrasound and alpha-fetoprotein for the diagnosis of hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013346] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
55 Sauzay C, Petit A, Bourgeois AM, Barbare JC, Chauffert B, Galmiche A, Houessinon A. Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. Clin Chim Acta. 2016;463:39-44. [PMID: 27732875 DOI: 10.1016/j.cca.2016.10.006] [Cited by in Crossref: 91] [Cited by in F6Publishing: 94] [Article Influence: 15.2] [Reference Citation Analysis]
56 Kim AK, Hamilton JP, Lin SY, Chang T, Hann H, Hu C, Lou Y, Lin Y, Gade TP, Park G, Luu H, Lee T, Wang J, Chen D, Goggins MG, Jain S, Song W, Su Y. Urine DNA biomarkers for hepatocellular carcinoma screening. Br J Cancer. [DOI: 10.1038/s41416-022-01706-9] [Reference Citation Analysis]
57 Hemming AW, Berumen J, Mekeel K. Hepatitis B and Hepatocellular Carcinoma. Clin Liver Dis. 2016;20:703-720. [PMID: 27742009 DOI: 10.1016/j.cld.2016.06.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
58 Wu T, Hatano E, Yamanaka K, Seo S, Taura K, Yasuchika K, Fujimoto Y, Nitta T, Mizumoto M, Mori A, Okajima H, Kaido T, Uemoto S. A non-smooth tumor margin on preoperative imaging predicts microvascular invasion of hepatocellular carcinoma. Surg Today 2016;46:1275-81. [DOI: 10.1007/s00595-016-1320-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
59 Qian Y, Wang JW, Fang Y, Yuan XD, Fan YC, Gao S, Wang K. Measurement of Cyclin D2 (CCND2) Gene Promoter Methylation in Plasma and Peripheral Blood Mononuclear Cells and Alpha-Fetoprotein Levels in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma. Med Sci Monit 2020;26:e927444. [PMID: 33320844 DOI: 10.12659/MSM.927444] [Reference Citation Analysis]
60 Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48. [PMID: 20207771 DOI: 10.1373/clinchem.2009.133124] [Cited by in Crossref: 146] [Cited by in F6Publishing: 119] [Article Influence: 12.2] [Reference Citation Analysis]
61 Tayob N, Stingo F, Do KA, Lok ASF, Feng Z. A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers. Biometrics 2018;74:249-59. [PMID: 28482112 DOI: 10.1111/biom.12717] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
62 Han LL, Lv Y, Guo H, Ruan ZP, Nan KJ. Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy. World J Gastroenterol 2014; 20(30): 10249-10261 [PMID: 25132742 DOI: 10.3748/wjg.v20.i30.10249] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
63 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 27] [Article Influence: 0.5] [Reference Citation Analysis]
64 Fu X, Wan S, Hann HW, Myers RE, Hann RS, Au J, Chen B, Xing J, Yang H. Relative telomere length: a novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection. Eur J Cancer 2012;48:1014-22. [PMID: 22444598 DOI: 10.1016/j.ejca.2012.02.066] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
65 Li F, Fan Y, Gao S, Sun F, Yang Y, Wang K. Methylation of serum insulin-like growth factor-binding protein 7 promoter in hepatitis B virus-associated hepatocellular carcinoma: Serum Igfbp7 Promoter Methylation in Hcc. Genes Chromosomes Cancer 2014;53:90-7. [DOI: 10.1002/gcc.22120] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
66 Wang G, Lu X, Du Q, Zhang G, Wang D, Wang Q, Guo X. Diagnostic value of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma. Sci Rep 2020;10:13519. [PMID: 32782270 DOI: 10.1038/s41598-020-70241-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Tunissiolli NM, Castanhole-Nunes MMU, Biselli-Chicote PM, Pavarino EC, da Silva RF, da Silva RC, Goloni-Bertollo EM. Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. Asian Pac J Cancer Prev. 2017;18:863-872. [PMID: 28545181 DOI: 10.22034/apjcp.2017.18.4.863] [Cited by in F6Publishing: 29] [Reference Citation Analysis]
68 Frankul L, Frenette C. Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol. 2021;9:220-226. [PMID: 34007804 DOI: 10.14218/jcth.2020.00037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Li J, Chen X, Dai M, Huang S, Chen J, Dai S. Diagnostic accuracy of osteopontin plus alpha-fetoprotein in the hepatocellular carcinoma: A meta-analysis. Clin Res Hepatol Gastroenterol 2017;41:543-53. [PMID: 28291627 DOI: 10.1016/j.clinre.2017.01.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
70 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022. [PMID: 21374666 DOI: 10.1002/hep.24199.] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
71 Yang JD, Kim WR. Surveillance for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10:16-21. [PMID: 21699816 DOI: 10.1016/j.cgh.2011.06.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
72 Sun Y, Gao G, Cai J, Wang Y, Qu X, He L, Liu F, Zhang Y, Lin K, Ma S, Yang X, Qian X, Zhao X. Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma. Carcinogenesis. 2013;34:595-604. [PMID: 23188673 DOI: 10.1093/carcin/bgs372] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
73 Sherman M. Modern Approach to Hepatocellular Carcinoma. Curr Gastroenterol Rep 2011;13:49-55. [DOI: 10.1007/s11894-010-0163-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
74 Shiota G, Miura N. Biomarkers for hepatocellular carcinoma. Clin J Gastroenterol 2012;5:177-82. [PMID: 26182317 DOI: 10.1007/s12328-012-0301-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
75 Xiong Y, Xie CR, Zhang S, Chen J, Yin ZY. Detection of a novel panel of somatic mutations in plasma cell-free DNA and its diagnostic value in hepatocellular carcinoma. Cancer Manag Res 2019;11:5745-56. [PMID: 31303788 DOI: 10.2147/CMAR.S197455] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
76 Du Z, Liu X, Wei X, Luo H, Li P, Shi M, Guo B, Cui Y, Su Z, Zeng J, Si A, Cao P, Zhou G. Quantitative proteomics identifies a plasma multi-protein model for detection of hepatocellular carcinoma. Sci Rep 2020;10:15552. [PMID: 32968147 DOI: 10.1038/s41598-020-72510-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
77 Lee J, Lim YS, Lee JH, Gwak GY, Do M, Yeo I, Shin D, Han D, Park T, Kim Y. Inclusive Quantification Assay of Serum Des-γ-Carboxyprothrombin Proteoforms for Hepatocellular Carcinoma Surveillance by Targeted Mass Spectrometry. Hepatol Commun 2021;5:1767-83. [PMID: 34558815 DOI: 10.1002/hep4.1752] [Reference Citation Analysis]
78 Yang JD, Dai J, Singal AG, Gopal P, Addissie BD, Nguyen MH, Befeler AS, Reddy KR, Schwartz M, Harnois DM, Yamada H, Gores GJ, Feng Z, Marrero JA, Roberts LR. Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. Cancer Epidemiol Biomarkers Prev 2017;26:1085-92. [PMID: 28258053 DOI: 10.1158/1055-9965.EPI-16-0747] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
79 Ao L, Zhang Z, Guan Q, Guo Y, Guo Y, Zhang J, Lv X, Huang H, Zhang H, Wang X, Guo Z. A qualitative signature for early diagnosis of hepatocellular carcinoma based on relative expression orderings. Liver Int 2018;38:1812-9. [PMID: 29682909 DOI: 10.1111/liv.13864] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
80 Du J, Hong J, Xu C, Cai Y, Xiang B, Zhou C, Xu X. Screening and Identification of ssDNA Aptamer for Human GP73. Biomed Res Int 2015;2015:610281. [PMID: 26583119 DOI: 10.1155/2015/610281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
81 Tanaka T, Taniguchi T, Sannomiya K, Takenaka H, Tomonari T, Okamoto K, Kitamura S, Okahisa T, Tamaki K, Mikasa H, Suzuki S, Takayama T. Novel des-γ-carboxy prothrombin in serum for the diagnosis of hepatocellular carcinoma. J Gastroenterol Hepatol 2013;28:1348-55. [PMID: 23432345 DOI: 10.1111/jgh.12166] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
82 Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, Waljee AK, Singal AG. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018; 154: 1706-1718. e1. [PMID: 29425931 DOI: 10.1053/j.gastro.2018.01.064] [Cited by in Crossref: 242] [Cited by in F6Publishing: 236] [Article Influence: 60.5] [Reference Citation Analysis]
83 Lee HJ, Yeon JE, Suh SJ, Lee SJ, Yoon EL, Kang K, Yoo YJ, Kim JH, Seo YS, Yim HJ. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver. 2014;8:177-185. [PMID: 24672660 DOI: 10.5009/gnl.2014.8.2.177] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
84 He Y, Lu H, Zhang L. Serum AFP levels in patients suffering from 47 different types of cancers and noncancer diseases. Prog Mol Biol Transl Sci 2019;162:199-212. [PMID: 30905450 DOI: 10.1016/bs.pmbts.2019.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
85 Masuda T, Miyoshi E. Cancer biomarkers for hepatocellular carcinomas: from traditional markers to recent topics. Clin Chem Lab Med 2011;49:959-66. [PMID: 21428856 DOI: 10.1515/CCLM.2011.152] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
86 Czaja AJ. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther 2013;38:343-64. [DOI: 10.1111/apt.12381] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
87 Sherman M. Hepatocellular carcinoma: screening and staging. Clin Liver Dis. 2011;15:323-324, vii-x. [PMID: 21689616 DOI: 10.1016/j.cld.2011.03.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
88 Arai T, Kobayashi A, Ohya A, Takahashi M, Yokoyama T, Shimizu A, Motoyama H, Furusawa N, Notake T, Kitagawa N. Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization. Int J Clin Oncol. 2014;19:871-879. [PMID: 24218280 DOI: 10.1007/s10147-013-0634-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
89 Peng JL, Wu JZ, Li GJ, Wu JL, Xi YM, Li XQ, Wang L. Identification of potential biomarkers of peripheral blood mononuclear cell in hepatocellular carcinoma using bioinformatic analysis: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e24172. [PMID: 33466191 DOI: 10.1097/MD.0000000000024172] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
90 De J, Shen Y, Qin J, Feng L, Wang Y, Yang L. A Systematic Review of Des-γ-Carboxy Prothrombin for the Diagnosis of Primary Hepatocellular Carcinoma. Medicine (Baltimore). 2016;95:e3448. [PMID: 27124038 DOI: 10.1097/md.0000000000003448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Vongsuvanh R, van der Poorten D, Iseli T, Strasser SI, McCaughan GW, George J. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. PLoS One. 2016;11:e0155800. [PMID: 27219517 DOI: 10.1371/journal.pone.0155800] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
92 Minami T, Tateishi R, Kondo M, Nakagomi R, Fujiwara N, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Moriya K, Shiina S, Koike K. Serum Alpha-Fetoprotein Has High Specificity for the Early Detection of Hepatocellular Carcinoma After Hepatitis C Virus Eradication in Patients. Medicine (Baltimore) 2015;94:e901. [PMID: 26061310 DOI: 10.1097/MD.0000000000000901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
93 Moldogazieva NT, Mokhosoev IM, Zavadskiy SP, Terentiev AA. Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine. Biomedicines 2021;9:159. [PMID: 33562077 DOI: 10.3390/biomedicines9020159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
94 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0] [Cited by in Crossref: 2892] [Cited by in F6Publishing: 1689] [Article Influence: 289.2] [Reference Citation Analysis]
95 Wang X, Zhang W, Liu Y, Gong W, Sun P, Kong X, Yang M, Wang Z. Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma. Infect Agent Cancer. 2017;12:47. [PMID: 28852419 DOI: 10.1186/s13027-017-0153-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
96 Borges KA, Dai J, Parikh ND, Schwartz M, Nguyen MH, Roberts LR, Befeler AS, Srivastava S, Rinaudo JA, Feng Z, Marrero JA, Reddy KR. Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network. Contemp Clin Trials 2019;76:49-54. [PMID: 30439517 DOI: 10.1016/j.cct.2018.11.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
97 Ricco G, Cosma C, Bedogni G, Biasiolo A, Guarino M, Pontisso P, Morisco F, Oliveri F, Cavallone D, Bonino F, Plebani M, Brunetto MR. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma. Cancer Biomark 2020;29:189-96. [PMID: 32623383 DOI: 10.3233/CBM-190118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
98 Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 262-274 [PMID: 26755875 DOI: 10.3748/wjg.v22.i1.262] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 61] [Article Influence: 11.5] [Reference Citation Analysis]
99 Liu C, Wu H, Mao Y, Chen W, Chen S. Exosomal microRNAs in hepatocellular carcinoma. Cancer Cell Int 2021;21:254. [PMID: 33964930 DOI: 10.1186/s12935-021-01941-9] [Reference Citation Analysis]
100 Kennedy P, Lewis S, Bane O, Hectors SJ, Kim E, Schwartz M, Taouli B. Early effect of 90Y radioembolisation on hepatocellular carcinoma and liver parenchyma stiffness measured with MR elastography: initial experience. Eur Radiol 2021;31:5791-801. [PMID: 33475773 DOI: 10.1007/s00330-020-07636-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Chen D, Jain S, Su YH, Song W. Building Classification Models with Combined Biomarker Tests: Application to Early Detection of Liver Cancer. J Stat Sci Appl 2017;5:91-103. [PMID: 29152526 DOI: 10.17265/2328-224X/2017.0506.002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
102 Yu R, Ding S, Tan W, Tan S, Tan Z, Xiang S, Zhou Y, Mao Q, Deng G. Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population. Hepat Mon. 2015;15:e28806. [PMID: 26300931 DOI: 10.5812/hepatmon.28806v2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
103 Singal AG, Marrero JA. Recent advances in the treatment of hepatocellular carcinoma: . Current Opinion in Gastroenterology 2010;26:189-95. [DOI: 10.1097/mog.0b013e3283383ca5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
104 Zhang X, Thiéfin G, Gobinet C, Untereiner V, Taleb I, Bernard-chabert B, Heurgué A, Truntzer C, Ducoroy P, Hillon P, Sockalingum GD. Profiling serologic biomarkers in cirrhotic patients via high-throughput Fourier transform infrared spectroscopy: toward a new diagnostic tool of hepatocellular carcinoma. Translational Research 2013;162:279-86. [DOI: 10.1016/j.trsl.2013.07.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
105 Sultanik P, Ginguay A, Vandame J, Popovici T, Meritet JF, Cynober L, Pol S, Bories PN. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse® G600 analyzer. J Viral Hepat 2017;24:80-5. [PMID: 27699936 DOI: 10.1111/jvh.12622] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
106 Cheng J, Wang W, Sun C, Li M, Wang B, Lv Y. Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol 2014;48:806-14. [PMID: 24247813 DOI: 10.1097/MCG.0000000000000018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
107 Lai Q, Melandro F, Pinheiro RS, Donfrancesco A, Fadel BA, Levi Sandri GB, Rossi M, Berloco PB, Frattaroli FM. Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again. Int J Hepatol. 2012;2012:893103. [PMID: 22792474 DOI: 10.1155/2012/893103] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
108 Campion D, Tucci A, Ponzo P, Caviglia GP. Non-invasive biomarkers for the detection of hepatocellular carcinoma. Minerva Biotecnol 2019;31. [DOI: 10.23736/s1120-4826.18.02488-6] [Cited by in Crossref: 13] [Article Influence: 4.3] [Reference Citation Analysis]
109 Hassett M, Yopp AC, Singal AG, Palmer BF. Surveillance for Hepatocellular Carcinoma: How Can We Do Better? The American Journal of the Medical Sciences 2013;346:308-13. [DOI: 10.1097/maj.0b013e31828318ff] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
110 Díaz-González Á, Forner A. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2016;30:1001-10. [PMID: 27938779 DOI: 10.1016/j.bpg.2016.10.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
111 Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, Lacaille F, Kelly D, Mieli-vergani G. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines. Journal of Hepatology 2013;59:814-29. [DOI: 10.1016/j.jhep.2013.05.016] [Cited by in Crossref: 121] [Cited by in F6Publishing: 100] [Article Influence: 13.4] [Reference Citation Analysis]
112 Feng L, Wang Y, Wang X, An S, Aizimuaji Z, Tao C, Zhang K, Cheng S, Wu J, Xiao T, Rong W. Integrated analysis of the rhesus monkey liver transcriptome during development and human primary HCC AFP-related gene expression. Mol Ther Nucleic Acids 2021;25:406-15. [PMID: 34484865 DOI: 10.1016/j.omtn.2021.06.004] [Reference Citation Analysis]
113 Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410-433. [PMID: 22846859 DOI: 10.1053/j.seminoncol.2012.05.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 10.3] [Reference Citation Analysis]
114 Erstad DJ, Tanabe KK. Hepatocellular carcinoma: early-stage management challenges. J Hepatocell Carcinoma 2017;4:81-92. [PMID: 28721349 DOI: 10.2147/JHC.S107370] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
115 Mossad NA, Mahmoud EH, Osman EA, Mahmoud SH, Shousha HI. Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IGM) and alpha-L-fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma. Tumour Biol. 2014;35:11559-11564. [PMID: 25129443 DOI: 10.1007/s13277-014-2467-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
116 Wen YH, Chang PY, Hsu CM, Wang HY, Chiu CT, Lu JJ. Cancer screening through a multi-analyte serum biomarker panel during health check-up examinations: Results from a 12-year experience. Clin Chim Acta 2015;450:273-6. [PMID: 26344337 DOI: 10.1016/j.cca.2015.09.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
117 Weledji EP, Enow Orock G, Ngowe MN, Nsagha DS. How grim is hepatocellular carcinoma? Ann Med Surg (Lond) 2014;3:71-6. [PMID: 25568791 DOI: 10.1016/j.amsu.2014.06.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
118 Örmeci N. Surveillance of the Patients with High Risk of Hepatocellular Cancer. J Gastrointest Cancer 2017;48:246-9. [PMID: 28634670 DOI: 10.1007/s12029-017-9972-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
119 Bhutiani N, O'brien SJ, Priddy EE, Egger ME, Hong YK, Mercer MK, Mcmasters KM, Martin RC, Potts MH, Scoggins CR. Correlating serum alpha-fetoprotein in hepatocellular carcinoma with response to Yttrium-90 transarterial radioembolization with glass microspheres (TheraSphere™). HPB 2020;22:1330-8. [DOI: 10.1016/j.hpb.2019.12.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
120 Yang JD, Patel T. Early Detection of Hepatocellular Carcinoma: Expanding the Utility of Circulating Tumor Markers. Hepatology 2019;69:1855-7. [PMID: 30556586 DOI: 10.1002/hep.30468] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
121 Alunni-Fabbroni M, Rönsch K, Huber T, Cyran CC, Seidensticker M, Mayerle J, Pech M, Basu B, Verslype C, Benckert J, Malfertheiner P, Ricke J. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. J Transl Med 2019;17:328. [PMID: 31570105 DOI: 10.1186/s12967-019-2079-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
122 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
123 Chen VL, Xu D, Wicha MS, Lok AS, Parikh ND. Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review. Clin Gastroenterol Hepatol 2020; 18: 2879-2902. e9. [PMID: 32289533 DOI: 10.1016/j.cgh.2020.04.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
124 Caviglia GP, Abate ML, Petrini E, Gaia S, Rizzetto M, Smedile A. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection: Highly sensitive HCC biomarkers. Hepatol Res 2016;46:E130-5. [DOI: 10.1111/hepr.12544] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
125 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 667] [Article Influence: 132.2] [Reference Citation Analysis]
126 Ferrín G, Aguilar-Melero P, Rodríguez-Perálvarez M, Montero-Álvarez JL, de la Mata M. Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility. Hepat Med 2015;7:1-10. [PMID: 25926760 DOI: 10.2147/HMER.S50161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
127 Ram AK, Pottakat B, Vairappan B. Increased systemic zonula occludens 1 associated with inflammation and independent biomarker in patients with hepatocellular carcinoma. BMC Cancer. 2018;18:572. [PMID: 29776350 DOI: 10.1186/s12885-018-4484-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
128 Lin S, Chen C, Lee K, Tseng C, Lin H, Chen Y, Lin H. DR-70 immunoassay for the surveillance of hepatocellular carcinoma: DR-70 for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2012;27:547-52. [DOI: 10.1111/j.1440-1746.2011.06896.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
129 Hao PP, Liu YP, Yang CY, Liang T, Zhang C, Song J, Han JK, Hou GH. Evaluation of (131)I-anti-angiotensin II type 1 receptor monoclonal antibody as a reporter for hepatocellular carcinoma. PLoS One 2014;9:e85002. [PMID: 24416333 DOI: 10.1371/journal.pone.0085002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
130 Ng CKY, Di Costanzo GG, Terracciano LM, Piscuoglio S. Circulating Cell-Free DNA in Hepatocellular Carcinoma: Current Insights and Outlook. Front Med (Lausanne). 2018;5:78. [PMID: 29632864 DOI: 10.3389/fmed.2018.00078] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
131 Hwang SH, Hong SB, Han K, Seo N, Choi JY, Lee JH, Park S, Lim YS, Kim DY, Kim SY, Park MS. A New Reporting System for Diagnosis of Hepatocellular Carcinoma in Chronic Hepatitis B With Clinical and Gadoxetic Acid-Enhanced MRI Features. J Magn Reson Imaging 2021. [PMID: 34668595 DOI: 10.1002/jmri.27962] [Reference Citation Analysis]
132 Yang JD. Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clin Mol Hepatol 2019;25:335-43. [PMID: 30924328 DOI: 10.3350/cmh.2019.0010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
133 Liu W, Xu W, Chen Y, Gu L, Sun X, Qu Y, Zhang H, Liu X, Huang H. Elevated double-strand break repair protein RAD50 predicts poor prognosis in hepatitis B virus-related hepatocellular carcinoma: A study based on Chinese high-risk cohorts. J Cancer 2020;11:5941-52. [PMID: 32922536 DOI: 10.7150/jca.46703] [Reference Citation Analysis]
134 Shen W, Ning J, Yuan Y, Lok AS, Feng Z. Model-free scoring system for risk prediction with application to hepatocellular carcinoma study. Biometrics 2018;74:239-48. [PMID: 28742219 DOI: 10.1111/biom.12750] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
135 Ferrín G, Ranchal I, Llamoza C, Rodríguez-Perálvarez ML, Romero-Ruiz A, Aguilar-Melero P, López-Cillero P, Briceño J, Muntané J, Montero-Álvarez JL, De la Mata M. Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE. Liver Int 2014;34:438-46. [PMID: 23944848 DOI: 10.1111/liv.12277] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
136 Di Poto C, Ferrarini A, Zhao Y, Varghese RS, Tu C, Zuo Y, Wang M, Nezami Ranjbar MR, Luo Y, Zhang C, Desai CS, Shetty K, Tadesse MG, Ressom HW. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery. Cancer Epidemiol Biomarkers Prev. 2017;26:675-683. [PMID: 27913395 DOI: 10.1158/1055-9965.epi-16-0366] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
137 Saitta C, Raffa G, Alibrandi A, Brancatelli S, Lombardo D, Tripodi G, Raimondo G, Pollicino T. PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients. Medicine (Baltimore) 2017;96:e7266. [PMID: 28658121 DOI: 10.1097/MD.0000000000007266] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
138 Han C, Gao L, Zhao L, Sheng Q, Zhang C, An Z, Xia T, Ding Y, Wang J, Bai H, Dou X. Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma. Med Sci Monit. 2018;24:7414-7423. [PMID: 30328412 DOI: 10.12659/msm.910738] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
139 Taura N, Ichikawa T, Miyaaki H, Ozawa E, Tsutsumi T, Tsuruta S, Kato Y, Goto T, Kinoshita N, Fukushima M, Kato H, Ohata K, Ohba K, Masuda J, Hamasaki K, Yatsuhashi H, Nakao K. Frequency of elevated biomarkers in patients with cryptogenic hepatocellular carcinoma. Med Sci Monit 2013;19:742-50. [PMID: 24008520 DOI: 10.12659/MSM.889361] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
140 Wang JW, Qian Y, Wu CS, Zhao NH, Fang Y, Yuan XD, Gao S, Fan YC, Wang K. Combined use of murine double minute-2 promoter methylation and serum AFP improves diagnostic efficiency in hepatitis B virus-related hepatocellular carcinoma. Int J Med Sci 2020;17:3190-9. [PMID: 33173438 DOI: 10.7150/ijms.47003] [Reference Citation Analysis]
141 Shen JD, Fu SZ, Ju LL, Wang YF, Dai F, Liu ZX, Ji HZ, Shao JG, Bian ZL. High expression of ubiquitin-conjugating enzyme E2A predicts poor prognosis in hepatocellular carcinoma. Oncol Lett 2018;15:7362-8. [PMID: 29725449 DOI: 10.3892/ol.2018.8189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
142 Li H, Wang Y, Ma S, Zhang C, Liu H, Sun D. Clinical significance of small molecule metabolites in the blood of patients with different types of liver injury. Sci Rep 2021;11:11642. [PMID: 34079030 DOI: 10.1038/s41598-021-91164-9] [Reference Citation Analysis]
143 Jiang Y, Tie C, Wang Y, Bian D, Liu M, Wang T, Ren Y, Liu S, Bai L, Chen Y, Duan Z, Zheng S, Zhang J. Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis. Front Oncol 2020;10:1759. [PMID: 33014866 DOI: 10.3389/fonc.2020.01759] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
144 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
145 Wu Y, Ma J, Wang Y, Zhang Y, Hou Y, Zhang C, Sun H, Sun J, Wang Z, Li N. Development of an alpha-fetoprotein and Golgi protein 73 multiplex detection assay using xMAP technology. Clin Chim Acta 2018;482:209-14. [PMID: 29630871 DOI: 10.1016/j.cca.2018.03.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
146 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
147 Milgrom DP, Maluccio MA, Koniaris LG. Management of Hepatocellular Carcinoma (HCC). Curr Surg Rep 2016;4. [DOI: 10.1007/s40137-016-0143-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
148 Morota K, Nakagawa M, Sekiya R, Hemken PM, Sokoll LJ, Elliott D, Chan DW, Dowell BL. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Clin Chem Lab Med. 2011;49:711-718. [PMID: 21231906 DOI: 10.1515/cclm.2011.097] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
149 Goossens N, Bian CB, Hoshida Y. Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated? Curr Hepatol Rep 2017;16:64-71. [PMID: 28337405 DOI: 10.1007/s11901-017-0336-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
150 Li L, Diao W, Zen K. Micro-ribonucleic acids: potential noninvasive biomarkers for hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:21-33. [PMID: 27508173 DOI: 10.2147/JHC.S44463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
151 Kim DY, Kim JW, Kuromatsu R, Ahn SH, Torimura T, Sherman M. Controversies in surveillance and early diagnosis of hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:56-60. [PMID: 22212937 DOI: 10.1159/000333261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
152 Zheng Y, Brown M, Lok A, Cai T. IMPROVING EFFICIENCY IN BIOMARKER INCREMENTAL VALUE EVALUATION UNDER TWO-PHASE DESIGNS. Ann Appl Stat 2017;11:638-54. [PMID: 28943991 DOI: 10.1214/16-AOAS997] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
153 Li CL, Ho MC, Lin YY, Tzeng ST, Chen YJ, Pai HY, Wang YC, Chen CL, Lee YH, Chen DS, Yeh SH, Chen PJ. Cell-Free Virus-Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer. Hepatology 2020;72:2063-76. [PMID: 32171027 DOI: 10.1002/hep.31230] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
154 Merchante N, Rodríguez-Fernández M, Pineda JA. Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. Curr HIV/AIDS Rep 2020;17:6-17. [PMID: 31933273 DOI: 10.1007/s11904-019-00475-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
155 Devcic Z, Elboraey M, Vidal L, Mody K, Harnois D, Patel T, Toskich BB. Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum. Semin Intervent Radiol 2019;36:287-97. [PMID: 31680719 DOI: 10.1055/s-0039-1698755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
156 Carrillo-Linares JL, García-Fernández MI, Morillo MJ, Sánchez P, Rioja J, Barón FJ, Ariza MJ, Harrington DJ, Card D, Boraldi F, Quaglino D, Valdivielso P. The Effects of Parenteral K1 Administration in Pseudoxanthoma Elasticum Patients Versus Controls. A Pilot Study. Front Med (Lausanne) 2018;5:86. [PMID: 29713628 DOI: 10.3389/fmed.2018.00086] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
157 Ferrín G, Rodríguez-Perálvarez M, Aguilar-Melero P, Ranchal I, Llamoza C, Linares CI, González-Rubio S, Muntané J, Briceño J, López-Cillero P, Montero-Álvarez JL, de la Mata M. Plasma protein biomarkers of hepatocellular carcinoma in HCV-infected alcoholic patients with cirrhosis. PLoS One 2015;10:e0118527. [PMID: 25789864 DOI: 10.1371/journal.pone.0118527] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
158 Tian MM, Fan YC, Zhao J, Gao S, Zhao ZH, Chen LY, Wang K. Hepatocellular carcinoma suppressor 1 promoter hypermethylation in serum. A diagnostic and prognostic study in hepatitis B. Clin Res Hepatol Gastroenterol 2017;41:171-80. [PMID: 28189396 DOI: 10.1016/j.clinre.2016.10.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
159 Ramachandran J. Surveillance for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S50-S56. [PMID: 25755611 DOI: 10.1016/j.jceh.2014.03.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
160 Esfeh JM, Hajifathalian K, Ansari-Gilani K. Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard. Clin Mol Hepatol. 2020;26:54-59. [PMID: 31726817 DOI: 10.3350/cmh.2019.0039] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
161 Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok AS, Lee WM. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013;108:425-432. [PMID: 23337478 DOI: 10.1038/ajg.2012.449] [Cited by in Crossref: 133] [Cited by in F6Publishing: 124] [Article Influence: 14.8] [Reference Citation Analysis]
162 Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol 2020;26:261-79. [PMID: 32536045 DOI: 10.3350/cmh.2020.0032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
163 Wang T, Zhang KH, Hu PP, Huang ZY, Zhang P, Wan QS, Huang DQ, Lv NH. Simple and robust diagnosis of early, small and AFP-negative primary hepatic carcinomas: an integrative approach of serum fluorescence and conventional blood tests. Oncotarget 2016;7:64053-70. [PMID: 27590520 DOI: 10.18632/oncotarget.11771] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
164 Meer SV, Man RA, Siersema PD, Erpecum KJV. Surveillance for hepatocellular carcinoma in chronic liver disease: Evidence and controversies. World J Gastroenterol 2013; 19(40): 6744-6756 [PMID: 24187450 DOI: 10.3748/wjg.v19.i40.6744] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
165 Degasperi E, Perbellini R, D'Ambrosio R, Uceda Renteria SC, Ceriotti F, Perego A, Orsini C, Borghi M, Iavarone M, Bruccoleri M, Rimondi A, De Silvestri A, Sangiovanni A, Lampertico P. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. Aliment Pharmacol Ther 2021. [PMID: 34738664 DOI: 10.1111/apt.16685] [Reference Citation Analysis]
166 Kobashi H, Miyake Y, Ikeda F, Yasunaka T, Nishino K, Moriya A, Kubota J, Nakamura S, Takaki A, Nouso K, Yamada G, Yamamoto K. Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol Res 2011;41:405-16. [PMID: 21435126 DOI: 10.1111/j.1872-034X.2011.00785.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
167 Asham EH, Kaseb A, Ghobrial RM. Management of Hepatocellular Carcinoma. Surgical Clinics of North America 2013;93:1423-50. [DOI: 10.1016/j.suc.2013.08.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
168 Yu R, Xiang X, Tan Z, Zhou Y, Wang H, Deng G. Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients. Sci Rep 2016;6:35050. [PMID: 27731353 DOI: 10.1038/srep35050] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
169 Qin Z, Wang J, Wang Y, Wang G, Wang X, Zhou Z, Liu G, Gao S, Zhu L. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection. Macromol Biosci 2017;17:1600335. [DOI: 10.1002/mabi.201600335] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
170 Hsu CY, Liu PH, Lee YH, Hsia CY, Huang YH, Lin HC, Chiou YY, Lee FY, Huo TI. Using serum α-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff? PLoS One. 2015;10:e0118825. [PMID: 25738614 DOI: 10.1371/journal.pone.0118825] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
171 Park SJ, Jang JY, Jeong SW, Cho YK, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Park S, Bang HI. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. Medicine (Baltimore). 2017;96:e5811. [PMID: 28296720 DOI: 10.1097/md.0000000000005811] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 8.6] [Reference Citation Analysis]
172 Worland T, Harrison B, Delmenico L, Dowling D. Hepatocellular Carcinoma Screening Utilising Serum Alpha-Fetoprotein Measurement and Abdominal Ultrasound Is More Effective than Ultrasound Alone in Patients with Non-viral Cirrhosis. J Gastrointest Cancer 2018;49:476-80. [PMID: 28920172 DOI: 10.1007/s12029-017-0006-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
173 Wang J, Huang A, Wang YP, Yin Y, Fu PY, Zhang X, Zhou J. Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma. Ann Transl Med 2020;8:237. [PMID: 32309384 DOI: 10.21037/atm.2019.12.154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
174 Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman WR, Chintharlapalli S, Abada PB, Sherman M, Zhu AX. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39:2214-2229. [PMID: 31436873 DOI: 10.1111/liv.14223] [Cited by in Crossref: 60] [Cited by in F6Publishing: 68] [Article Influence: 20.0] [Reference Citation Analysis]
175 Wong RJ, Ahmed A, Gish RG. Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders. Clin Liver Dis. 2015;19:309-323. [PMID: 25921665 DOI: 10.1016/j.cld.2015.01.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 7.6] [Reference Citation Analysis]
176 Parikh ND, Mehta AS, Singal AG, Block T, Marrero JA, Lok AS. Biomarkers for the Early Detection of Hepatocellular Carcinoma.Cancer Epidemiol Biomarkers Prev. 2020;29:2495-2503. [PMID: 32238405 DOI: 10.1158/1055-9965.EPI-20-0005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
177 Yao S, Zhang J, Chen H, Sheng Y, Zhang X, Liu Z, Zhang C. Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma. J Histochem Cytochem. 2013;61:639-648. [PMID: 23686365 DOI: 10.1369/0022155413492771] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
178 El-Serag HB, Kanwal F. α-Fetoprotein in hepatocellular carcinoma surveillance: mend it but do not end it. Clin Gastroenterol Hepatol. 2013;11:441-443. [PMID: 23376321 DOI: 10.1016/j.cgh.2012.12.046] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
179 Yang L, Bai Y, Han X, Shi Y, Liu H. Plasma Lipidomic Analysis to Identify Novel Biomarkers for Hepatocellular Carcinoma. J Anal Test 2017;1:223-32. [DOI: 10.1007/s41664-017-0028-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
180 Hann HW, Fu X, Myers RE, Hann RS, Wan S, Kim SH, Au N, Xing J, Yang H. Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection--results from a clinic-based longitudinal cohort. Eur J Cancer. 2012;48:2319-2327. [PMID: 22436980 DOI: 10.1016/j.ejca.2012.02.065] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
181 Ali HEA, Abdel Hameed R, Effat H, Ahmed EK, Atef AA, Sharawi SK, Ali M, Abd Elmageed ZY, Abdel Wahab AH. Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2017;41:e51-e62. [PMID: 28750770 DOI: 10.1016/j.clinre.2017.06.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
182 Nishida N, Arizumi T, Takita M, Nagai T, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K. Quantification of tumor DNA in serum and vascular invasion of human hepatocellular carcinoma. Oncology. 2013;84 Suppl 1:82-87. [PMID: 23428864 DOI: 10.1159/000345895] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
183 Carr BI, Akkiz H, Üsküdar O, Yalçın K, Guerra V, Kuran S, Karaoğullarından Ü, Altıntaş E, Özakyol A, Tokmak S, Ballı T, Yücesoy M, Bahçeci Hİ, Ülkü A, Akçam T, Polat KY, Ekinci N, Şimşek H, Örmeci N, Sonsuz A, Demir M, Kılıç M, Uygun A, Demir A, Delik A, Arslan B, Doran F, Yilmaz S, Tokat Y. HCC with low- and normal-serum alpha-fetoprotein levels. Clin Pract (Lond). 2018;15:453-464. [PMID: 29576865 DOI: 10.4172/clinical-practice.1000393] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
184 Lozada ME, Chaiteerakij R, Roberts LR. Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging? Curr Hepatol Rep 2015;14:128-38. [PMID: 26328266 DOI: 10.1007/s11901-015-0261-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
185 Liu W, Zhang A, Xu G, Wei F, Yang J, Hu Q. Manganese modified CdTe/CdS quantum dots as an immunoassay biosensor for the detection of Golgi protein-73. Journal of Pharmaceutical and Biomedical Analysis 2016;117:18-25. [DOI: 10.1016/j.jpba.2015.08.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
186 Ye Z, Zeng Z, Shen Y, Chen Z. Identification of hub genes in peripheral blood mononuclear cells for the diagnosis of hepatocellular carcinoma using a weighted gene co-expression network analysis. Exp Ther Med 2020;20:890-900. [PMID: 32742331 DOI: 10.3892/etm.2020.8736] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
187 Gailhouste L, Liew LC, Yasukawa K, Hatada I, Tanaka Y, Nakagama H, Ochiya T. Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells. Mol Ther 2018;26:1840-54. [PMID: 29759938 DOI: 10.1016/j.ymthe.2018.04.018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
188 Panda D. Role of surveillance in prevention of hepatocellular carcinoma. J Clin Exp Hepatol 2014;4:S43-9. [PMID: 25755610 DOI: 10.1016/j.jceh.2014.03.044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
189 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 718] [Article Influence: 230.0] [Reference Citation Analysis]
190 Truong BX, Yano Y, VAN VT, Seo Y, Nam NH, Trach NK, Utsumi T, Azuma T, Hayashi Y. Clinical utility of protein induced by vitamin K absence in patients with chronic hepatitis B virus infection. Biomed Rep. 2013;1:122-128. [PMID: 24648907 DOI: 10.3892/br.2012.4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
191 Fitian AI, Cabrera R. Disease monitoring of hepatocellular carcinoma through metabolomics. World J Hepatol 2017; 9(1): 1-17 [PMID: 28105254 DOI: 10.4254/wjh.v9.i1.1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
192 Liu D, Cai T, Lok A, Zheng Y. Nonparametric Maximum Likelihood Estimators of Time-Dependent Accuracy Measures for Survival Outcome Under Two-Stage Sampling Designs. J Am Stat Assoc 2018;113:882-92. [PMID: 30555194 DOI: 10.1080/01621459.2017.1295866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
193 Yin H, Lin Z, Nie S, Wu J, Tan Z, Zhu J, Dai J, Feng Z, Marrero J, Lubman DM. Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma. J Proteome Res. 2014;13:2887-2896. [PMID: 24799124 DOI: 10.1021/pr500043k] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
194 Yonet-Tanyeri N, Ahlmark BZ, Little SR. Advances in Multiplexed Paper-Based Analytical Devices for Cancer Diagnosis: A Review of Technological Developments. Adv Mater Technol 2021;6:2001138. [PMID: 34447879 DOI: 10.1002/admt.202001138] [Reference Citation Analysis]
195 Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19-37. [PMID: 24367230 DOI: 10.2147/hmer.s16316] [Cited by in Crossref: 39] [Cited by in F6Publishing: 132] [Article Influence: 3.9] [Reference Citation Analysis]
196 Han C, Gao L, Bai H, Dou X. Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma. Oncol Lett 2018;16:7123-30. [PMID: 30546447 DOI: 10.3892/ol.2018.9547] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
197 Thein HH, Campitelli MA, Yeung LT, Zaheen A, Yoshida EM, Earle CC. Improved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study. PLoS One 2015;10:e0138907. [PMID: 26398404 DOI: 10.1371/journal.pone.0138907] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
198 Li B, Li B, Guo T, Sun Z, Li X, Li X, Chen L, Zhao J, Mao Y. Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of α-fetoprotein, α-fetoprotein-L3, des-γ-carboxy prothrombin, and Golgi protein 73. Oncotarget 2017;8:80521-30. [PMID: 29113322 DOI: 10.18632/oncotarget.19298] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
199 Tang B, Wang J, Hutchison JA, Ma L, Zhang N, Guo H, Hu Z, Li M, Zhao Y. Ultrasensitive, Multiplex Raman Frequency Shift Immunoassay of Liver Cancer Biomarkers in Physiological Media. ACS Nano 2016;10:871-9. [PMID: 26731464 DOI: 10.1021/acsnano.5b06007] [Cited by in Crossref: 72] [Cited by in F6Publishing: 57] [Article Influence: 12.0] [Reference Citation Analysis]
200 Arnone OC, Serranti D, Bartolini E, Mastrangelo G, Stinco M, Trapani S, Ricci S, Resti M, Indolfi G. Chronic hepatitis B in children, report of a single-centre longitudinal study on 152 children. J Viral Hepat. 2020;27:1344-1351. [PMID: 32853482 DOI: 10.1111/jvh.13382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
201 Chang ML, Lin SM, Yeh CT. HURP expression-assisted risk scores identify prognosis distinguishable subgroups in early stage liver cancer. PLoS One 2011;6:e26323. [PMID: 22022601 DOI: 10.1371/journal.pone.0026323] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
202 Sherman M. Surveillance for hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2014;28:783-93. [DOI: 10.1016/j.bpg.2014.08.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
203 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
204 Zhang X, Xu Y, Qian Z, Zheng W, Wu Q, Chen Y, Zhu G, Liu Y, Bian Z, Xu W, Zhang Y, Sun F, Pan Q, Wang J, Du L, Yu Y. circRNA_104075 stimulates YAP-dependent tumorigenesis through the regulation of HNF4a and may serve as a diagnostic marker in hepatocellular carcinoma. Cell Death Dis 2018;9:1091. [PMID: 30361504 DOI: 10.1038/s41419-018-1132-6] [Cited by in Crossref: 81] [Cited by in F6Publishing: 96] [Article Influence: 20.3] [Reference Citation Analysis]
205 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
206 Yang T, Xing H, Wang G, Wang N, Liu M, Yan C, Li H, Wei L, Li S, Fan Z, Shi M, Chen W, Cai S, Pawlik TM, Soh A, Beshiri A, Lau WY, Wu M, Zheng Y, Shen F. A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B. Clin Chem. 2019;65:1543-1553. [PMID: 31672853 DOI: 10.1373/clinchem.2019.308965] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
207 Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, Rapaccini GL, Anna Di Nolfo M, Benvegnù L, Zoli M. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology. 2012;56:1371-1379. [PMID: 22535689 DOI: 10.1002/hep.25814] [Cited by in Crossref: 77] [Cited by in F6Publishing: 81] [Article Influence: 8.6] [Reference Citation Analysis]
208 Cabrera R, Fitian AI, Ararat M, Xu Y, Brusko T, Wasserfall C, Atkinson MA, Liu C, Nelson DR. Serum levels of soluble CD25 as a marker for hepatocellular carcinoma. Oncol Lett. 2012;4:840-846. [PMID: 23205111 DOI: 10.3892/ol.2012.826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
209 Kim GA, Seock CH, Park JW, An J, Lee KS, Yang JE, Lim YS, Kim KM, Shim JH, Lee D. Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment. Liver Int. 2015;35:232-239. [PMID: 24576055 DOI: 10.1111/liv.12516] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
210 Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Yoshida H, Aoki T, Hasegawa K, Akahane M, Ohtomo K, Fukayama M, Koike K, Kokudo N. Diagnostic accuracy of α-fetoprotein and des-γ-carboxy prothrombin in screening for hepatocellular carcinoma in liver transplant candidates: AFP and DCP in transplant candidates. Hepatology Research 2011;41:1199-207. [DOI: 10.1111/j.1872-034x.2011.00871.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
211 Ahmed Mohammed HF, Roberts LR. Should AFP (or any biomarkers) be used for HCC surveillance? Curr Hepatol Rep 2017;16:137-45. [PMID: 29085770 DOI: 10.1007/s11901-017-0349-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
212 Li J, Liao Y, Suo L, Zhu P, Chen X, Dang W, Liao M, Qin L, Liao W. A novel prognostic index-neutrophil times γ-glutamyl transpeptidase to lymphocyte ratio (NγLR) predicts outcome for patients with hepatocellular carcinoma. Sci Rep 2017;7:9229. [PMID: 28835713 DOI: 10.1038/s41598-017-09696-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
213 Umezu T, Tsuneyama K, Kanekura K, Hayakawa M, Tanahashi T, Kawano M, Taguchi YH, Toyoda H, Tamori A, Kuroda M, Murakami Y. Comprehensive analysis of liver and blood miRNA in precancerous conditions. Sci Rep 2020;10:21766. [PMID: 33303811 DOI: 10.1038/s41598-020-78500-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
214 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
215 Biasiolo A, Martini A, Pontisso P. New biomarkers for clinical management of hepatitis C virus infected patients. World J Clin Infect Dis 2015; 5(4): 59-66 [DOI: 10.5495/wjcid.v5.i4.59] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
216 Francica G, Borzio M. Status of, and strategies for improving, adherence to HCC screening and surveillance. J Hepatocell Carcinoma 2019;6:131-41. [PMID: 31440486 DOI: 10.2147/JHC.S159269] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
217 Ma XL, Zhou JY, Gao XH, Tian L, Wu J, Zhang CY, Zhou Y, Dai Q, Wang BL, Pan BS, Yang XR, Guo W. Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma. Clin Chim Acta. 2016;462:15-22. [PMID: 27520748 DOI: 10.1016/j.cca.2016.08.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
218 El-Gebaly F, Abou-Saif S, Elkadeem M, Helmy A, Abd-Elsalam S, Yousef M, Elkhouly RA, Amer IF, El-Demerdash T. Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients. Curr Cancer Drug Targets 2019;19:896-905. [PMID: 31538897 DOI: 10.2174/1568009619666190718141647] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
219 Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, Fan J, Yang XR, Zhou J. Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity. J Cancer. 2016;7:1907-1914. [PMID: 27698932 DOI: 10.7150/jca.15823] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
220 Nishio T, Hatano E, Sakurai T, Taura K, Okuno M, Kasai Y, Seo S, Yasuchika K, Mori A, Kaido T, Uemoto S. Impact of Hepatic Steatosis on Disease-Free Survival in Patients with Non-B Non-C Hepatocellular Carcinoma Undergoing Hepatic Resection. Ann Surg Oncol 2015;22:2226-34. [PMID: 25395147 DOI: 10.1245/s10434-014-4181-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
221 Chiang JK, Chih-Wen L, Kao YH. Effect of ultrasonography surveillance in patients with liver cancer: a population-based longitudinal study. BMJ Open 2017;7:e015936. [PMID: 28645973 DOI: 10.1136/bmjopen-2017-015936] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
222 Zhou Q, Zhou C, Yin Y, Chen W, Liu C, Atyah M, Weng J, Shen Y, Yi Y, Ren N. Development and validation of a nomogram combining hematological and imaging features for preoperative prediction of microvascular invasion in hepatocellular carcinoma patients. Ann Transl Med 2021;9:402. [PMID: 33842623 DOI: 10.21037/atm-20-4695] [Reference Citation Analysis]
223 Chiappini F. Circulating tumor cells measurements in hepatocellular carcinoma. Int J Hepatol. 2012;2012:684802. [PMID: 22690340 DOI: 10.1155/2012/684802] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
224 Fartoux L, Decaens T. Contribution of biomarkers and imaging in the management of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2011;35 Suppl 1:S21-S30. [PMID: 21742297 DOI: 10.1016/s2210-7401(11)70004-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
225 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
226 Song T, Wang L, Su B, Zeng W, Jiang T, Zhang T, Sun G, Wu H. Diagnostic value of alpha-fetoprotein, Lens culinaris agglutinin-reactive alpha-fetoprotein, and des-gamma-carboxyprothrombin in hepatitis B virus-related hepatocellular carcinoma. J Int Med Res 2020;48:300060519889270. [PMID: 31852373 DOI: 10.1177/0300060519889270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
227 Rong G, Wang H, Bowlus CL, Wang C, Lu Y, Zeng Z, Qu J, Lou M, Chen Y, An L. Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015;48:132-141. [PMID: 25762349 DOI: 10.1007/s12016-015-8483-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
228 Kim YI, Kim HS, Park JW. Higher Ratio of Serum Alpha-Fetoprotein Could Predict Outcomes in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma and Normal Alanine Aminotransferase. PLoS One. 2016;11:e0157299. [PMID: 27304617 DOI: 10.1371/journal.pone.0157299] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
229 Ayoub WS, Steggerda J, Yang JD, Kuo A, Sundaram V, Lu SC. Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers. Ther Adv Med Oncol. 2019;11:1758835919869120. [PMID: 31523283 DOI: 10.1177/1758835919869120] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
230 Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol. 2012;107:64-74. [PMID: 21931376 DOI: 10.1038/ajg.2011.312] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 6.7] [Reference Citation Analysis]
231 Wu J, Xiang Z, Bai L, He L, Tan L, Hu M, Ren Y. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA. Cancer Biomark. 2018;23:235-242. [PMID: 30103302 DOI: 10.3233/cbm-181402] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
232 Kyei-Barffour I, Kwarkoh RKB, Acheampong DO, Brah AS, Akwetey SA, Aboagye B. Alkaloidal extract from Carica papaya seeds ameliorates CCl4-induced hepatocellular carcinoma in rats. Heliyon 2021;7:e07849. [PMID: 34471716 DOI: 10.1016/j.heliyon.2021.e07849] [Reference Citation Analysis]
233 Mikami S, Tateishi R, Hagiwara S, Sato M, Minami T, Uchino K, Enooku K, Sato T, Nakagawa H, Masuzaki R, Asaoka Y, Kondo Y, Shiina S, Ikeda H, Omata M, Yoshida H, Koike K. Tumor markers are more useful in patients undergoing surveillance for hepatocellular carcinoma with unreliable results by ultrasonography. Hepatol Res 2015;45:415-22. [PMID: 24861870 DOI: 10.1111/hepr.12365] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
234 Sherman M. Histological diagnosis of early hepatocellular carcinoma. Hepatology 2011;53:1427-9. [PMID: 21452287 DOI: 10.1002/hep.24332] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
235 Ette AI, Ndububa DA, Adekanle O, Ekrikpo U. Utility of serum des-gamma-carboxyprothrombin in the diagnosis of hepatocellular carcinoma among Nigerians, a case-control study. BMC Gastroenterol 2015;15:113. [PMID: 26341083 DOI: 10.1186/s12876-015-0344-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
236 Dunn BK, Wagner PD, Anderson D, Greenwald P. Molecular markers for early detection. Semin Oncol 2010;37:224-42. [PMID: 20709207 DOI: 10.1053/j.seminoncol.2010.05.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
237 Lou J, Zhang L, Lv S, Zhang C, Jiang S. Biomarkers for Hepatocellular Carcinoma. Biomark Cancer. 2017;9:1-9. [PMID: 28469485 DOI: 10.1177/1179299x16684640] [Cited by in Crossref: 61] [Cited by in F6Publishing: 41] [Article Influence: 12.2] [Reference Citation Analysis]
238 Komatsu H, Inui A, Yoshio S, Fujisawa T. Pharmacotherapy options for managing hepatitis B in children. Expert Opin Pharmacother 2021;22:449-67. [PMID: 33090882 DOI: 10.1080/14656566.2020.1841165] [Reference Citation Analysis]
239 Suzuki H, Murata K, Gotoh T, Kusano M, Okano H, Oyamada T, Yasuda Y, Imamura M, Kudo M, Mizokami M. Phenotype-dependent production of des-γ-carboxy prothrombin in hepatocellular carcinoma. J Gastroenterol. 2011;46:1219-1229. [PMID: 21744129 DOI: 10.1007/s00535-011-0432-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
240 Chung JW, Kim BH, Lee CS, Kim GH, Sohn HR, Min BY, Song JC, Park HK, Jang ES, Yoon H, Kim J, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Lee J, Ahn S, Kim JW. Optimizing Surveillance Performance of Alpha-Fetoprotein by Selection of Proper Target Population in Chronic Hepatitis B. PLoS One 2016;11:e0168189. [PMID: 27997559 DOI: 10.1371/journal.pone.0168189] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
241 Hallager S, Ladelund S, Kjaer M, Madsen LG, Belard E, Laursen AL, Gerstoft J, Røge BT, Grønbaek KE, Krarup HB, Christensen PB, Weis N. Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: A nationwide cohort study. J Viral Hepat 2018;25:47-55. [PMID: 28750141 DOI: 10.1111/jvh.12764] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
242 Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: A systematic review. Hepatol Res. 2014;44:E11-E25. [PMID: 23834468 DOI: 10.1111/hepr.12201] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
243 Poté N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, Castera L, Puy H, Bedossa P, Paradis V. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol. 2015;62:848-854. [PMID: 25450201 DOI: 10.1016/j.jhep.2014.11.005] [Cited by in Crossref: 117] [Cited by in F6Publishing: 127] [Article Influence: 14.6] [Reference Citation Analysis]
244 Bodzin AS, Busuttil RW. Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol 2015; 7(9): 1157-1167 [PMID: 26019732 DOI: 10.4254/wjh.v7.i9.1157] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 7.0] [Reference Citation Analysis]
245 Chang TS, Wu YC, Tung SY, Wei KL, Hsieh YY, Huang HC, Chen WM, Shen CH, Lu CH, Wu CS. Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. Am J Gastroenterol. 2015;110:836-844; quiz 845. [PMID: 25869392 DOI: 10.1038/ajg.2015.100] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 8.9] [Reference Citation Analysis]
246 Dinges SS, Hohm A, Vandergrift LA, Nowak J, Habbel P, Kaltashov IA, Cheng LL. Cancer metabolomic markers in urine: evidence, techniques and recommendations. Nat Rev Urol 2019;16:339-62. [PMID: 31092915 DOI: 10.1038/s41585-019-0185-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 20.5] [Reference Citation Analysis]
247 Nanashima A, Abo T, Nonaka T, Fukuoka H, Hidaka S, Takeshita H, Ichikawa T, Sawai T, Yasutake T, Nakao K. Prognosis of patients with hepatocellular carcinoma after hepatic resection: are elderly patients suitable for surgery? J Surg Oncol. 2011;104:284-291. [PMID: 21462192 DOI: 10.1002/jso.21932] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 5.4] [Reference Citation Analysis]
248 Mandon CA, Berthuy OI, Corgier BP, Le Goff GC, Faure P, Marche PN, Blum LJ, Marquette CA. Polymer adhesive surface as flexible generic platform for multiplexed assays biochip production. Biosens Bioelectron 2013;39:37-43. [PMID: 22795528 DOI: 10.1016/j.bios.2012.06.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
249 Ying X, Zhu X, Li D, Li X. Preparation and specific recognition of protein macromolecularly imprinted polyampholyte hydrogel. Talanta 2019;192:14-23. [DOI: 10.1016/j.talanta.2018.08.084] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
250 Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tanaka J, Kagebayashi C, Satomura S. High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. J Gastroenterol. 2014;49:555-563. [PMID: 24057163 DOI: 10.1007/s00535-013-0883-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
251 Zhang A, Yin C, Wang Z, Zhang Y, Zhao Y, Li A, Sun H, Lin D, Li N. Development and application of a fluorescence protein microarray for detecting serum alpha-fetoprotein in patients with hepatocellular carcinoma. J Int Med Res 2016;44:1414-23. [PMID: 27885040 DOI: 10.1177/0300060516672370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
252 Liao X, Han C, Qin W, Liu X, Yu L, Zhu G, Yu T, Lu S, Su H, Liu Z, Chen Z, Yang C, Huang K, Liu Z, Liang Y, Huang J, Dong J, Li L, Qin X, Ye X, Xiao K, Peng M, Peng T. PLCE1 polymorphisms and expression combined with serum AFP level predicts survival of HBV-related hepatocellular carcinoma patients after hepatectomy. Oncotarget 2017;8:29202-19. [PMID: 28418898 DOI: 10.18632/oncotarget.16346] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
253 Hemken PM, Sokoll LJ, Yang X, Dai J, Elliott D, Gawel SH, Lucht M, Feng Z, Marrero JA, Srivastava S, Chan DW, Davis GJ. Validation of a novel model for the early detection of hepatocellular carcinoma. Clin Proteomics. 2019;16:2. [PMID: 30675135 DOI: 10.1186/s12014-018-9222-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
254 Xie D, Zhu WF, Cheng H, Yao ZY, Li M, Zhao YL. An antibody-free assay for simultaneous capture and detection of glycoproteins by surface enhanced Raman spectroscopy. Phys Chem Chem Phys 2018;20:8881-6. [DOI: 10.1039/c7cp08478a] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
255 Qu C, Wang Y, Wang P, Chen K, Wang M, Zeng H, Lu J, Song Q, Diplas BH, Tan D, Fan C, Guo Q, Zhu Z, Yin H, Jiang L, Chen X, Zhao H, He H, Li G, Bi X, Zhao X, Chen T, Tang H, Lv C, Wang D, Chen W, Zhou J, Cai J, Wang X, Wang S, Yan H, Zeng YX, Cavenee WK, Jiao Y. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. Proc Natl Acad Sci USA. 2019;116:6308-6312. [PMID: 30858324 DOI: 10.1073/pnas.1819799116] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 15.3] [Reference Citation Analysis]
256 Maziarz M, Cai T, Qi L, Lok AS, Zheng Y. Evaluating longitudinal markers under two-phase study designs. Biostatistics 2019;20:485-98. [PMID: 29912281 DOI: 10.1093/biostatistics/kxy013] [Reference Citation Analysis]
257 Viggiani V, Palombi S, Gennarini G, D’ettorre G, De Vito C, Angeloni A, Frati L, Anastasi E. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients. Scandinavian Journal of Gastroenterology 2016;51:1257-62. [DOI: 10.1080/00365521.2016.1183705] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
258 Kobayashi T, Ichihara K, Goda S, Hidaka I, Yamasaki T, Ishida H. Exploration and time-serial validation of logistic regression models composed of multiple laboratory tests for early detection of HCV-associated hepatocellular carcinoma. Clin Chim Acta 2021;521:137-43. [PMID: 34153275 DOI: 10.1016/j.cca.2021.06.022] [Reference Citation Analysis]
259 He W, Li B, Zheng Y, Zou R, Shen J, Cheng D, Tao Q, Liu W, Li Q, Chen G, Yuan Y. Resection vs. ablation for alpha-fetoprotein positive hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Int 2016;36:1677-87. [DOI: 10.1111/liv.13166] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
260 Flores A, Marrero JA. Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol 2014;8:71-6. [PMID: 24899827 DOI: 10.4137/CMO.S9926] [Cited by in Crossref: 90] [Cited by in F6Publishing: 54] [Article Influence: 11.3] [Reference Citation Analysis]
261 Ricco G, Cavallone D, Cosma C, Caviglia GP, Oliveri F, Biasiolo A, Abate ML, Plebani M, Smedile A, Bonino F, Pontisso P, Brunetto MR. Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers.Cancer Biomark. 2018;21:603-612. [PMID: 29278878 DOI: 10.3233/CBM-170551] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
262 Tayob N, Lok AS, Do KA, Feng Z. Improved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm. Clin Gastroenterol Hepatol 2016;14:469-475.e2. [PMID: 26260109 DOI: 10.1016/j.cgh.2015.07.049] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
263 Abd El Gwad A, Matboli M, El-Tawdi A, Habib EK, Shehata H, Ibrahim D, Tash F. Role of exosomal competing endogenous RNA in patients with hepatocellular carcinoma. J Cell Biochem 2018;119:8600-10. [PMID: 30015383 DOI: 10.1002/jcb.27109] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
264 Schütte K, Schulz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol 2015; 7(2): 139-149 [PMID: 25729470 DOI: 10.4254/wjh.v7.i2.139] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
265 Lim YS. Role of Tumor Biomarkers in the Surveillance of Hepatocellular Carcinoma. Korean J Gastroenterol 2021;78:284-8. [PMID: 34824186 DOI: 10.4166/kjg.2021.137] [Reference Citation Analysis]
266 Jang ES, Jeong SH, Kim JW, Choi YS, Leissner P, Brechot C. Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma. PLoS One. 2016;11:e0151069. [PMID: 26986465 DOI: 10.1371/journal.pone.0151069] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
267 Beudeker BJB, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. Therap Adv Gastroenterol 2020;13:1756284820931734. [PMID: 32647536 DOI: 10.1177/1756284820931734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
268 Xie J, Zhang A, Wang X. Metabolomic applications in hepatocellular carcinoma: toward the exploration of therapeutics and diagnosis through small molecules. RSC Adv 2017;7:17217-26. [DOI: 10.1039/c7ra00698e] [Cited by in Crossref: 13] [Article Influence: 2.6] [Reference Citation Analysis]
269 Zeng G, Gill US, Kennedy PTF. Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis. Gut 2020;69:1907-12. [PMID: 32451325 DOI: 10.1136/gutjnl-2020-321627] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
270 Bruix J, Sherman M;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022. [PMID: 21374666 DOI: 10.1002/hep.24199] [Cited by in Crossref: 5422] [Cited by in F6Publishing: 5185] [Article Influence: 492.9] [Reference Citation Analysis]
271 Gomaa SH, Abaza MM, Elattar HA, Amin GA, Elshahawy DM. Soluble cluster of differentiation 26/soluble dipeptidyl peptidase-4 and glypican-3 are promising serum biomarkers for the early detection of Hepatitis C virus related hepatocellular carcinoma in Egyptians. Arab J Gastroenterol 2020;21:224-32. [PMID: 32891543 DOI: 10.1016/j.ajg.2020.04.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
272 Rahimi R, Yopp A, Singal A. Current issues and future trends in surveillance for hepatocellular carcinoma. Clin Liver Disease. 2012;1:186-189. [PMID: 31186884 DOI: 10.1002/cld.115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
273 Ao J, Chiba T, Kanzaki H, Kanayama K, Shibata S, Kurosugi A, Iwanaga T, Kan M, Sakuma T, Qiang N, Ma Y, Kojima R, Kusakabe Y, Nakamura M, Kobayashi K, Kiyono S, Kanogawa N, Saito T, Nakagawa R, Kondo T, Ogasawara S, Suzuki E, Nakamoto S, Muroyama R, Tawada A, Kato J, Kanda T, Maruyama H, Kato N. Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma. J Cancer 2021;12:2694-701. [PMID: 33854629 DOI: 10.7150/jca.56436] [Reference Citation Analysis]
274 Buadu A, Meyer MA. Small Liver Nodule Detection With a High-Frequency Transducer in Patients With Chronic Liver Disease: Report of 3 cases. Journal of Ultrasound in Medicine 2013;32:355-9. [DOI: 10.7863/jum.2013.32.2.355] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
275 Kim DY, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012;1:2-14. [PMID: 24159567 DOI: 10.1159/000339016] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 9.1] [Reference Citation Analysis]
276 Imai N, Kinoshita A, Onoda H, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Tajiri H. Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma. Clin Transl Oncol 2013;15:575-81. [PMID: 23263911 DOI: 10.1007/s12094-012-0976-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
277 Peyton A, Martin P. Primary Care of Patients with Cirrhosis – Current and Future Challenges. Curr Hepatology Rep 2014;13:1-7. [DOI: 10.1007/s11901-014-0219-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
278 Sánchez-Lorencio MI, Saenz L, Ramirez P, Villalba-López F, de la Orden V, Mediero-Valeros B, Revilla Nuin B, Gonzalez MR, Cascales-Campos PA, Ferreras-Martínez D, Noguera-Velasco JA, Díaz-Rubio E, Parrilla P. Matrix Metalloproteinase 1 as a Novel Biomarker for Monitoring Hepatocellular Carcinoma in Liver Transplant Patients. Transplant Proc 2018;50:623-7. [PMID: 29579870 DOI: 10.1016/j.transproceed.2017.11.061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
279 Banini BA, Sanyal AJ. The use of cell free DNA in the diagnosis of HCC. Hepatoma Res 2019;5:34. [PMID: 31673629 DOI: 10.20517/2394-5079.2019.30] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
280 Ma X, Ding Y, Zeng L. The diagnostic and prognostic value of H2AFY in hepatocellular carcinoma. BMC Cancer 2021;21:418. [PMID: 33858382 DOI: 10.1186/s12885-021-08161-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
281 Wang Y, Yang H, Xu H, Lu X, Sang X, Zhong S, Huang J, Mao Y. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis. J Gastroenterol Hepatol. 2014;29:597-602. [PMID: 24236824 DOI: 10.1111/jgh.12461] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
282 Mohamed BF, Serag WM, Abdelal RM, Elsergany HF. S100A14 protein as diagnostic and prognostic marker in hepatocellular carcinoma. Egypt Liver Journal 2019;9. [DOI: 10.1186/s43066-019-0015-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
283 Hass HG, Vogel U, Scheurlen M, Jobst J. Subclassification and Detection of New Markers for the Discrimination of Primary Liver Tumors by Gene Expression Analysis Using Oligonucleotide Arrays. Gut Liver 2018;12:306-15. [PMID: 29271183 DOI: 10.5009/gnl17277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
284 Moriya K, Namisaki T, Sato S, Furukawa M, Douhara A, Kawaratani H, Kaji K, Shimozato N, Sawada Y, Saikawa S, Takaya H, Kitagawa K, Akahane T, Mitoro A, Yamao J, Yoshiji H. Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients. Clin Mol Hepatol. 2019;25:381-389. [PMID: 31405269 DOI: 10.3350/cmh.2019.0037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
285 Suk KT, Kim EJ, Kim DJ, Kim HS, Bang CS, Park TY, Baik GH, Kim SE, Park JW, Park SH, Lee MS, Kim HS, Jang MK, Park SH, Choi E, Kim CH, Sung H, Park CK. Prognostic Significance of Hemodynamic and Clinical Stages in the Prediction of Hepatocellular Carcinoma. J Clin Gastroenterol 2017;51:285-93. [PMID: 27661973 DOI: 10.1097/MCG.0000000000000671] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
286 Biselli M, Conti F, Gramenzi A, Frigerio M, Cucchetti A, Fatti G, D'Angelo M, Dall'Agata M, Giannini EG, Farinati F, Ciccarese F, Andreone P, Bernardi M, Trevisani F. A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. Br J Cancer 2015;112:69-76. [PMID: 25314061 DOI: 10.1038/bjc.2014.536] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
287 Mehta AS, Lau DT, Wang M, Aslam A, Nasir B, Javaid A, Poongkunran M, Block TM. Application of the Doylestown algorithm for the early detection of hepatocellular carcinoma. PLoS One 2018;13:e0203149. [PMID: 30169533 DOI: 10.1371/journal.pone.0203149] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
288 Chen F, Zhang F, Liu Y, Cai C. Simply and sensitively simultaneous detection hepatocellular carcinoma markers AFP and miRNA-122 by a label-free resonance light scattering sensor. Talanta 2018;186:473-80. [PMID: 29784390 DOI: 10.1016/j.talanta.2018.04.060] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
289 Abu El Makarem MA, Abdel-aleem A, Ali A, Saber R, Shatat M, Rahem DA, Sayed D. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Annals of Hepatology 2011;10:296-305. [DOI: 10.1016/s1665-2681(19)31541-8] [Cited by in Crossref: 40] [Article Influence: 3.6] [Reference Citation Analysis]
290 Bolondi L, Gramantieri L. From liver cirrhosis to HCC. Intern Emerg Med 2011;6 Suppl 1:93-8. [PMID: 22009618 DOI: 10.1007/s11739-011-0682-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
291 Willatt J, Ruma JA, Azar SF, Dasika NL, Syed F. Imaging of hepatocellular carcinoma and image guided therapies - how we do it. Cancer Imaging 2017;17:9. [PMID: 28259177 DOI: 10.1186/s40644-017-0110-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
292 Han JJ, Chen Y, Nan YC, Yang YL. Extremely high titer of hepatitis B surface antigen antibodies in a primary hepatocellular carcinoma patient: A case report. World J Clin Cases 2021; 9(28): 8492-8497 [PMID: 34754858 DOI: 10.12998/wjcc.v9.i28.8492] [Reference Citation Analysis]
293 Hennedige T, Venkatesh SK. Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imaging. 2013;12:530-547. [PMID: 23400006 DOI: 10.1102/1470-7330.2012.0044] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 9.6] [Reference Citation Analysis]
294 Sohda T, Iwata K, Anan A, Kunimoto H, Yotsumoto K, Yokoyama K, Morihara D, Takeyama Y, Shakado S, Osame A, Kora S, Ohishi J, Yamauchi Y, Noritomi T, Yoshimitsu K, Yamashita Y, Sakisaka S. Upregulation of des-gamma-carboxy-prothrombin after portal vein embolization in a cirrhotic patient with hepatocellular carcinoma. Clin J Gastroenterol 2015;8:330-4. [PMID: 26374567 DOI: 10.1007/s12328-015-0603-x] [Reference Citation Analysis]
295 Conti F, Dall'Agata M, Gramenzi A, Biselli M. Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis. Biomark Med 2015;9:1343-51. [PMID: 26580585 DOI: 10.2217/bmm.15.100] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
296 Bachtiar I, Kheng V, Wibowo GA, Gani RA, Hasan I, Sanityoso A, Budhihusodo U, Lelosutan SA, Martamala R, Achwan WA. Alpha-1-acid glycoprotein as potential biomarker for alpha-fetoprotein-low hepatocellular carcinoma. BMC Res Notes. 2010;3:319. [PMID: 21092242 DOI: 10.1186/1756-0500-3-319] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
297 Delacourt AT, Mehta AS. Liver Cancer (Current Therapies). Reference Module in Biomedical Sciences. Elsevier; 2021. [DOI: 10.1016/b978-0-12-820472-6.00007-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
298 Li T, Li H, Wang A, Su X, Zhao J, Cui Y, Liu J, Hu J. Development And Validation Of A Simple Model For Detection Of Early Hepatocellular Carcinoma In A Liver Cirrhosis Cohort. Cancer Manag Res 2019;11:9379-86. [PMID: 31807067 DOI: 10.2147/CMAR.S221050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
299 Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016;25:74-85. [PMID: 27312032 DOI: 10.1016/j.suronc.2016.03.002] [Cited by in Crossref: 165] [Cited by in F6Publishing: 175] [Article Influence: 27.5] [Reference Citation Analysis]
300 Tran QH, Nguyen VG, Tran CM, Nguyen MN. Down-regulation of solute carrier family 10 member 1 is associated with early recurrence and poorer prognosis of hepatocellular carcinoma. Heliyon 2021;7:e06463. [PMID: 33763615 DOI: 10.1016/j.heliyon.2021.e06463] [Reference Citation Analysis]
301 Nomura F, Sogawa K, Noda K, Seimiya M, Matsushita K, Miura T, Tomonaga T, Yoshitomi H, Imazeki F, Takizawa H. Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma. Biochem Biophys Res Commun. 2012;421:837-843. [PMID: 22554520 DOI: 10.1016/j.bbrc.2012.04.099] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
302 Yang JD, Addissie BD, Mara KC, Harmsen WS, Dai J, Zhang N, Wongjarupong N, Ali HM, Ali HA, Hassan FA, Lavu S, Cvinar JL, Giama NH, Moser CD, Miyabe K, Allotey LK, Algeciras-Schimnich A, Theobald JP, Ward MM, Nguyen MH, Befeler AS, Reddy KR, Schwartz M, Harnois DM, Yamada H, Srivastava S, Rinaudo JA, Gores GJ, Feng Z, Marrero JA, Roberts LR. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev. 2019;28:531-538. [PMID: 30464023 DOI: 10.1158/1055-9965.epi-18-0281] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
303 Biasiolo A, Trotta E, Fasolato S, Ruvoletto M, Martini A, Gallotta A, Fassina G, Angeli P, Gatta A, Pontisso P. Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study. Dig Liver Dis 2016;48:197-202. [PMID: 26614642 DOI: 10.1016/j.dld.2015.10.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
304 Otsuka K, Ochiya T. Possible connection between diet and microRNA in cancer scenario. Seminars in Cancer Biology 2021;73:4-18. [DOI: 10.1016/j.semcancer.2020.11.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
305 Shen M, Shen Y, Fan X, Men R, Ye T, Yang L. Roles of Macrophages and Exosomes in Liver Diseases. Front Med (Lausanne) 2020;7:583691. [PMID: 33072790 DOI: 10.3389/fmed.2020.583691] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
306 Lee YS, Ko E, Yoon EL, Jung YK, Kim JH, Seo YS, Yim HJ, Kim KH, Kwon SY, Yeon JE, Um SH, Byun KS. Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP. J Clin Med 2020;9:E323. [PMID: 31979338 DOI: 10.3390/jcm9020323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
307 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet 2018;391:1301-14. [DOI: 10.1016/s0140-6736(18)30010-2] [Cited by in Crossref: 1580] [Cited by in F6Publishing: 1003] [Article Influence: 395.0] [Reference Citation Analysis]
308 Simpson HN, McGuire BM. Screening and detection of hepatocellular carcinoma. Clin Liver Dis 2015;19:295-307. [PMID: 25921664 DOI: 10.1016/j.cld.2015.01.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
309 Sadik NA, Ahmed NR, Mohamed MF, Ashoush OA. Serum Vascular Endothelial Growth Factor in Patients with Hepatocellular Carcinoma and its Validity as a Tumor Biomarker. TOBIOMJ 2019;9:84-94. [DOI: 10.2174/1875318301909010084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
310 Reichl P, Mikulits W. Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review). Oncol Rep. 2016;36:613-625. [PMID: 27278244 DOI: 10.3892/or.2016.4842] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
311 Lee HA, Lee YR, Lee YS, Jung YK, Kim JH, An H, Yim HJ, Jeen YT, Yeon JE, Byun KS, Seo YS. Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein improves diagnostic accuracy for hepatocellular carcinoma. World J Gastroenterol 2021; 27(28): 4687-4696 [PMID: 34366629 DOI: 10.3748/wjg.v27.i28.4687] [Reference Citation Analysis]
312 Kim JU, Shariff MIF, Crossey MME, Gomez-Romero M, Holmes E, Cox IJ, Fye HKS, Njie R, Taylor-Robinson SD. Hepatocellular carcinoma: Review of disease and tumor biomarkers. World J Hepatol 2016; 8(10): 471-484 [PMID: 27057305 DOI: 10.4254/wjh.v8.i10.471] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
313 Zheng A, Zhang X, Gao J, Liu X, Liu J. Peroxidase-like catalytic activity of copper ions and its application for highly sensitive detection of glypican-3. Analytica Chimica Acta 2016;941:87-93. [DOI: 10.1016/j.aca.2016.08.036] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
314 Dadfar SMM, Sekula-Neuner S, Trouillet V, Liu HY, Kumar R, Powell AK, Hirtz M. Evaluation of click chemistry microarrays for immunosensing of alpha-fetoprotein (AFP). Beilstein J Nanotechnol 2019;10:2505-15. [PMID: 31921529 DOI: 10.3762/bjnano.10.241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
315 Kim MJ. Current limitations and potential breakthroughs for the early diagnosis of hepatocellular carcinoma. Gut Liver 2011;5:15-21. [PMID: 21461067 DOI: 10.5009/gnl.2011.5.1.15] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
316 Choi J, Kim GA, Han S, Lee W, Chun S, Lim YS. Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma. Hepatology. 2019;69:1983-1994. [PMID: 30153338 DOI: 10.1002/hep.30233] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 13.7] [Reference Citation Analysis]